MEDICAMEQ

Medicamen Biotech Share Price

₹433.55 -16.9 (-3.75%)

21 Nov, 2024 14:45

SIP TrendupStart SIP in MEDICAMEQ

Start SIP

Performance

  • Low
  • ₹430
  • High
  • ₹454
  • 52 Week Low
  • ₹355
  • 52 Week High
  • ₹661
  • Open Price₹450
  • Previous Close₹450
  • Volume9,508

Investment Returns

  • Over 1 Month -20.34%
  • Over 3 Month + 5.64%
  • Over 6 Month -19.13%
  • Over 1 Year -33.44%
SIP Lightning

Smart Investing Starts Here Start SIP with Medicamen Biotech for Steady Growth!

Invest Now

Medicamen Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 79.1
  • PEG Ratio
  • -1.7
  • Market Cap Cr
  • 551
  • P/B Ratio
  • 2.7
  • Average True Range
  • 29.83
  • EPS
  • 5.77
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -5.87
  • RSI
  • 36.41
  • MFI
  • 63.05

Medicamen Biotech Financials

Medicamen Biotech Technicals

EMA & SMA

Current Price
₹433.55
-16.9 (-3.75%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹495.05
  • 50 Day
  • ₹496.59
  • 100 Day
  • ₹488.71
  • 200 Day
  • ₹503.84

Resistance and Support

454.78 Pivot Speed
  • R3 487.27
  • R2 477.88
  • R1 464.17
  • S1 441.07
  • S2 431.68
  • S3 417.97

What's your outlook on Medicamen Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Medicamen Biotech Ltd specializes in the manufacturing and marketing of pharmaceutical formulations, including injectables, tablets, and syrups. The company serves domestic and international markets, focusing on quality, innovation, and regulatory compliance in the healthcare sector.

Medicamen Biotech has an operating revenue of Rs. 181.61 Cr. on a trailing 12-month basis. An annual revenue growth of 27% is outstanding, Pre-tax margin of 7% is okay, ROE of 5% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 25% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 27 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Medicamen Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-12 Quarterly Results
2023-11-10 Quarterly Results

Medicamen Biotech F&O

Medicamen Biotech Shareholding Pattern

42.99%
0%
0.06%
32.44%
24.51%

About Medicamen Biotech

  • NSE Symbol
  • MEDICAMEQ
  • BSE Symbol
  • 531146
  • ISIN
  • INE646B01010

Similar Stocks to Medicamen Biotech

Medicamen Biotech FAQs

Medicamen Biotech share price is ₹433 As on 21 November, 2024 | 14:31

The Market Cap of Medicamen Biotech is ₹551.2 Cr As on 21 November, 2024 | 14:31

The P/E ratio of Medicamen Biotech is 79.1 As on 21 November, 2024 | 14:31

The PB ratio of Medicamen Biotech is 2.7 As on 21 November, 2024 | 14:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23